DR. ROBERT DAVID KACHELHOFER, M.D.
Radiology in Birmingham, AL
License number
Alabama 25692
Category
Radiology
Type
Diagnostic Radiology
Address
Address
619 19 St. SOUTH, Birmingham, AL 35233
Phone
(205) 934-6600
(205) 871-4274
(205) 871-4301 (Fax)
(205) 871-4274
(205) 871-4301 (Fax)
Professional information
Robert David Kachelhofer, Birmingham AL
Specialties:
Radiologist
Address:
619 19Th St S, Birmingham, AL 35233
Education:
Doctor of Medicine
Board certifications:
American Board of Radiology Certification in Diagnostic Radiology (Radiology)
Independent Music Professional
Location:
Birmingham, Alabama Area
Industry:
Music
P-Cresol Sulfate, A Component Of Urinary Myelin Basic Protein-Like Material, As A Correlate Of Multiple Sclerosis Status
US Patent:
6284473, Sep 4, 2001
Filed:
Oct 6, 1999
Appl. No.:
9/412851
Inventors:
John Nicholas Whitaker - Birmingham AL
Robert David Kachelhofer - Birmingham AL
Edwin Luther Bradley - Birmingham AL
Sheila Loughran Burgard - Lake Bluff IL
Beverly Ann Layton - Birmingham AL
Anthony Thomas Reder - Oak Park IL
Wendy Jean Morrision - Vancouver, CA
Guojun Zhao - Burnaby, CA
Donald Winston Paty - Vancouver, CA
Ligong Cao - Birmingham AL
Lori Coward - Birmingham AL
Patricia L. Jackson - Moody AL
Marion Kirk - Birmingham AL
Robert David Kachelhofer - Birmingham AL
Edwin Luther Bradley - Birmingham AL
Sheila Loughran Burgard - Lake Bluff IL
Beverly Ann Layton - Birmingham AL
Anthony Thomas Reder - Oak Park IL
Wendy Jean Morrision - Vancouver, CA
Guojun Zhao - Burnaby, CA
Donald Winston Paty - Vancouver, CA
Ligong Cao - Birmingham AL
Lori Coward - Birmingham AL
Patricia L. Jackson - Moody AL
Marion Kirk - Birmingham AL
Assignee:
UAB Research Foundation - Birmingham AL
International Classification:
G01N 3353, G01N 33566, G01N 33567, G01N 33536
US Classification:
435 71
Abstract:
The present invention provides a method of determining the status of a multiple sclerosis patient, i. e. , predicting the transition from a status of relapsing-remitting to a progressive phase of multiple sclerosis, comprising the step of measuring the amount of urinary p-cresol sulfate in the patient. The present invention also provides a method of determining the amount of lesions and total lesion area of a multiple sclerosis patient, comprising the step of measuring the amount of urinary p-cresol sulfate in the patient. Further provided is a method of monitoring myelination in a developing child, comprising the step of: measuring the amount of p-cresol sulfate in the urine of said child.
Methods Of Measuring Urinary Myelin Basic Protein-Like Material
US Patent:
5998150, Dec 7, 1999
Filed:
Oct 1, 1996
Appl. No.:
8/723581
Inventors:
John Nicholas Whitaker - Birmingham AL
Robert David Kachelhofer - Birmingham AL
Beverly Ann Layton - Birmingham AL
Edwin Luther Bradley - Birmingham AL
Sheila Loughran Burgard - Lake Bluff IL
Anthony Thomas Reder - Oak Park IL
Wendy Jean Morrison - Vancouver, CA
Guojun Zhao - Vancouver, CA
Donald Winston Paty - Vancouver, CA
Robert David Kachelhofer - Birmingham AL
Beverly Ann Layton - Birmingham AL
Edwin Luther Bradley - Birmingham AL
Sheila Loughran Burgard - Lake Bluff IL
Anthony Thomas Reder - Oak Park IL
Wendy Jean Morrison - Vancouver, CA
Guojun Zhao - Vancouver, CA
Donald Winston Paty - Vancouver, CA
Assignee:
UAB Research Foundation - Birmingham AL
International Classification:
G01N 3353, G01N 33566, G01N 33567, G01N 33536
US Classification:
435 71
Abstract:
The present invention provides a method of determining the status of a multiple sclerosis patient, i. e. , predicting the transition from a status of relapsing-remitting to a progressive phase of multiple sclerosis, comprising the step of measuring the levels of urinary myelin basic protein-like material in the patient. The present invention also provides a method of determining the amount of lesions and total lesion area of a multiple sclerosis patient, comprising the step of measuring the levels of urinary myelin basic protein-like material in the patient. Further provided is a method of monitoring myelination in a developing child, comprising the step of: measuring the levels of myelin basic protein-like material in the urine of said child.